Gemma Turon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gemma Turon has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Miquel Duran-Frigola
Ersilia Open Source Initiative
7 shared publications - Kelly Chibale
University of Cape Town
6 shared publications - Jason Hlozek
Department of Chemistry and Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Cape Town, South Africa
3 shared publications - John G. Woodland
Department of Chemistry University of Cape Town Rondebosch, Cape Town 7701 South Africa
3 shared publications Anna Montaner
Ersilia Open Source Initiative, Barcelona, Spain
2 shared publications- Mathew Njoroge
Holistic Drug Discovery and Development (H3D) Centre University of Cape Town Cape Town South Africa
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (16) , 19593-19600
Bridging the AI Divide in Drug Discovery: Practical Lessons from Capacity Strengthening in Africa
Artificial Intelligence (AI) has become an integral part of drug discovery in high-income countries. However, these advances have yet to be broadly adopted by research ecosystems in many low- and middle-income countries in Africa, where understudied infectious diseases, compounded by a growing noncommunicable disease burden, cause millions of deaths each year. Given adequate support and appropriate models AI could play a transformative role in under-resourced biomedical research ecosystems in Africa, democratizing drug discovery research. There is an urgent need to invest in building the critical infrastructure, tools, and capacity required. To drive this agenda forward, Ersilia, the H3D Centre, and H3D Foundation with support from the AI2050 program at Schmidt Sciences hosted a series of in-person and online workshops in Africa to grow the AI skills base for medicinal chemistry and enable adoption across regional research hubs. In this perspective article, we discuss the lessons learnt from this program, the fit-for-purpose open-source tools developed, and key considerations for future initiatives.
- 7 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (16) , 19593-19600
Open AccessBridging the AI Divide in Drug Discovery: Practical Lessons from Capacity Strengthening in Africa
Artificial Intelligence (AI) has become an integral part of drug discovery in high-income countries. However, these advances have yet to be broadly adopted by research ecosystems in many low- and middle-income countries in Africa, where understudied infectious diseases, compounded by a growing noncommunicable disease burden, cause millions of deaths each year. Given adequate support and appropriate models AI could play a transformative role in under-resourced biomedical research ecosystems in Africa, democratizing drug discovery research. There is an urgent need to invest in building the critical infrastructure, tools, and capacity required. To drive this agenda forward, Ersilia, the H3D Centre, and H3D Foundation with support from the AI2050 program at Schmidt Sciences hosted a series of in-person and online workshops in Africa to grow the AI skills base for medicinal chemistry and enable adoption across regional research hubs. In this perspective article, we discuss the lessons learnt from this program, the fit-for-purpose open-source tools developed, and key considerations for future initiatives.
- Open Access
- 25 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 498
Addressing infectious diseases in Africa by accelerating drug discovery through data science
Despite being rich in natural resources and scientific talent, Africa continues to bear a staggering infectious disease burden. Historically, health innovation on the continent has relied on international funding and has been constrained by limited infrastructure and the emigration of skilled professionals. Data science tools offer a promising alternative, typically requiring fewer costly resources than traditional empirical research, with the potential to empower African scientists to generate tangible and impactful health solutions for the continent. Rapid progress in data science is expected to transform infectious disease research; thus, it is encouraging that numerous African initiatives are already applying data science tools to tackling pressing unmet medical needs, particularly in drug discovery. These efforts include identifying novel therapeutic targets, predicting drug-like molecules and their synthesis, enhancing clinical trial success rates and preparing for future disease threats. This review examines the current landscape of data science in infectious disease drug discovery across Africa.
- 25 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 498
Open AccessAddressing infectious diseases in Africa by accelerating drug discovery through data science
Despite being rich in natural resources and scientific talent, Africa continues to bear a staggering infectious disease burden. Historically, health innovation on the continent has relied on international funding and has been constrained by limited infrastructure and the emigration of skilled professionals. Data science tools offer a promising alternative, typically requiring fewer costly resources than traditional empirical research, with the potential to empower African scientists to generate tangible and impactful health solutions for the continent. Rapid progress in data science is expected to transform infectious disease research; thus, it is encouraging that numerous African initiatives are already applying data science tools to tackling pressing unmet medical needs, particularly in drug discovery. These efforts include identifying novel therapeutic targets, predicting drug-like molecules and their synthesis, enhancing clinical trial success rates and preparing for future disease threats. This review examines the current landscape of data science in infectious disease drug discovery across Africa.
- Open Access
- 20 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa
Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Our pipeline couples machine learning and artificial intelligence with physiologically-based pharmacokinetic (PBPK) and non-linear mixed effects (NLME) modelling to hypothesize which pharmacogenes could be of potential clinical interest, and which dose adjustments could be made to provide better treatment outcomes for African populations. Drug-gene pairs are first ranked with the latest knowledge embedding techniques, based on public structural and bioactivity data for drugs and genes, followed by a large language model-based refinement. Selected genes are then evaluated for their sensitivity in PBPK analysis, and relevant variants subsequently inspected with NLME for dose optimization. The analysis is focused on genes with potential clinical relevance in Africa. We delve deeper into malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective.
- 20 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open AccessArtificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa
Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Our pipeline couples machine learning and artificial intelligence with physiologically-based pharmacokinetic (PBPK) and non-linear mixed effects (NLME) modelling to hypothesize which pharmacogenes could be of potential clinical interest, and which dose adjustments could be made to provide better treatment outcomes for African populations. Drug-gene pairs are first ranked with the latest knowledge embedding techniques, based on public structural and bioactivity data for drugs and genes, followed by a large language model-based refinement. Selected genes are then evaluated for their sensitivity in PBPK analysis, and relevant variants subsequently inspected with NLME for dose optimization. The analysis is focused on genes with potential clinical relevance in Africa. We delve deeper into malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective.
- Open Access
- 23 November 2024
- Published by Wiley in Molecular Informatics
- Vol. 44 (1) , e202400293
The Chemical Space Spanned by Manually Curated Datasets of Natural and Synthetic Compounds with Activities against SARS‐CoV‐2
Diseases caused by viruses are challenging to contain, as their outbreak and spread could be very sudden, compounded by rapid mutations, making the development of drugs and vaccines a continued endeavour that requires fast discovery and preparedness. Targeting viral infections with small molecules remains one of the treatment options to reduce transmission and the disease burden. A lesson learned from the recent coronavirus disease (COVID‐19) is to collect ready‐to‐screen small molecule libraries in preparation for the next viral outbreak, and potentially find a clinical candidate before it becomes a pandemic. Public availability of diverse compound libraries, well annotated in terms of chemical structures and scaffolds, modes of action, and bioactivities are, therefore, crucial to ensure the participation of academic laboratories in these screening efforts, especially in resource‐limited settings where synthesis, testing and computing capacity are scarce. Here, we demonstrate a low‐resource approach to populate the chemical space of naturally occurring and synthetic small molecules that have shown in vitro and/or in vivo activities against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its target proteins. We have manually curated two datasets of small molecules (naturally occurring and synthetically derived) by reading and collecting (hand‐curating) the published literature. Information from the literature reveals that a majority of the reported SARS‐CoV‐2 compounds act by inhibiting the main protease, while 25% of the compounds currently have no known target. Scaffold analysis and principal component analysis revealed that the most common scaffolds in the datasets are quite distinct. We then expanded the initially manually curated dataset of over 1200 compounds via an ultra‐large scale 2D and 3D similarity search, obtaining an expanded collection of over 150 k purchasable compounds. The spanned chemical space significantly extends beyond that of a commercially available coronavirus library of more than 20 k small molecules and constitutes a good starting collection for virtual screening campaigns given its manageable size and proximity to hand‐curated compounds.
- 23 November 2024
- Published by Wiley in Molecular Informatics
- Vol. 44 (1) , e202400293
Open AccessThe Chemical Space Spanned by Manually Curated Datasets of Natural and Synthetic Compounds with Activities against SARS‐CoV‐2
Diseases caused by viruses are challenging to contain, as their outbreak and spread could be very sudden, compounded by rapid mutations, making the development of drugs and vaccines a continued endeavour that requires fast discovery and preparedness. Targeting viral infections with small molecules remains one of the treatment options to reduce transmission and the disease burden. A lesson learned from the recent coronavirus disease (COVID‐19) is to collect ready‐to‐screen small molecule libraries in preparation for the next viral outbreak, and potentially find a clinical candidate before it becomes a pandemic. Public availability of diverse compound libraries, well annotated in terms of chemical structures and scaffolds, modes of action, and bioactivities are, therefore, crucial to ensure the participation of academic laboratories in these screening efforts, especially in resource‐limited settings where synthesis, testing and computing capacity are scarce. Here, we demonstrate a low‐resource approach to populate the chemical space of naturally occurring and synthetic small molecules that have shown in vitro and/or in vivo activities against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its target proteins. We have manually curated two datasets of small molecules (naturally occurring and synthetically derived) by reading and collecting (hand‐curating) the published literature. Information from the literature reveals that a majority of the reported SARS‐CoV‐2 compounds act by inhibiting the main protease, while 25% of the compounds currently have no known target. Scaffold analysis and principal component analysis revealed that the most common scaffolds in the datasets are quite distinct. We then expanded the initially manually curated dataset of over 1200 compounds via an ultra‐large scale 2D and 3D similarity search, obtaining an expanded collection of over 150 k purchasable compounds. The spanned chemical space significantly extends beyond that of a commercially available coronavirus library of more than 20 k small molecules and constitutes a good starting collection for virtual screening campaigns given its manageable size and proximity to hand‐curated compounds.
- Open Access
AI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa
Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Furthermore, we delve deeper into the analysis of malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective. Our pipeline leverages artificial intelligence and the latest advances in knowledge embedding techniques to exploit currently available biomedical data and subsequently prioritise pharmacogenes for each drug. Predicted pharmacogenes are then incorporated into pharmacometric modelling to hypothesise which ones might be of clinical interest, and which dose adjustments could be made to provide better treatment outcomes for the African population.
Open AccessAI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa
Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Furthermore, we delve deeper into the analysis of malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective. Our pipeline leverages artificial intelligence and the latest advances in knowledge embedding techniques to exploit currently available biomedical data and subsequently prioritise pharmacogenes for each drug. Predicted pharmacogenes are then incorporated into pharmacometric modelling to hypothesise which ones might be of clinical interest, and which dose adjustments could be made to provide better treatment outcomes for the African population.
- Open Access
- 15 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-11
First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
Streamlined data-driven drug discovery remains challenging, especially in resource-limited settings. We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool for quantitative structure-activity/property relationship (QSAR/QSPR) modelling. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets. We describe an end-to-end implementation at the H3D Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. By leveraging in-house data collected over a decade, we have developed a virtual screening cascade for malaria and tuberculosis drug discovery comprising 15 models for key decision-making assays ranging from whole-cell phenotypic screening and cytotoxicity to aqueous solubility, permeability, microsomal metabolic stability, cytochrome inhibition, and cardiotoxicity. We show how computational profiling of compounds, prior to synthesis and testing, can inform progression of frontrunner compounds at H3D. This project is a first-of-its-kind deployment at scale of AI/ML tools in a research centre operating in a low-resource setting.
- 15 September 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-11
Open AccessFirst fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
Streamlined data-driven drug discovery remains challenging, especially in resource-limited settings. We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool for quantitative structure-activity/property relationship (QSAR/QSPR) modelling. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets. We describe an end-to-end implementation at the H3D Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. By leveraging in-house data collected over a decade, we have developed a virtual screening cascade for malaria and tuberculosis drug discovery comprising 15 models for key decision-making assays ranging from whole-cell phenotypic screening and cytotoxicity to aqueous solubility, permeability, microsomal metabolic stability, cytochrome inhibition, and cardiotoxicity. We show how computational profiling of compounds, prior to synthesis and testing, can inform progression of frontrunner compounds at H3D. This project is a first-of-its-kind deployment at scale of AI/ML tools in a research centre operating in a low-resource setting.
- Open Access
Machine learning approaches identify chemical features for stage-specific antimalarial compounds
Efficacy data from diverse chemical libraries, screened against the various stages of the malaria parasite Plasmodium falciparum , including asexual blood stage (ABS) parasites and transmissible gametocytes, serves as a valuable reservoir of information on the chemical space of compounds that are either active (or not) against the parasite. We postulated that this data can be mined to define chemical features associated with sole ABS activity and/or those that provide additional life cycle activity profiles like gametocytocidal activity. Additionally, this information could provide chemical features associated with inactive compounds, which could eliminate any future unnecessary screening of similar chemical analogues. Therefore, we aimed to use machine learning to identify the chemical space associated with stage-specific antimalarial activity. We collected data from various chemical libraries that were screened against the asexual (126 374 compounds) and sexual (gametocyte) stages of the parasite (93 941 compounds), calculated the compounds’ molecular fingerprints and trained machine learning models to recognize stage-specific active and inactiv compounds. We were able to build several models that predicts compound activity against ABS and dual-activity against ABS and gametocytes, with Support Vector Machines (SVM) showing superior abilities with high recall (90% and 66%) and low false positive predictions (15% and 1%). This allowed identification of chemical features enriched in active and inactive populations, an important outcome that could be mined for essential chemical features to streamline hit-to-lead optimization strategies of antimalarial candidates. The predictive capabilities of the models held true in diverse chemical spaces, indicating that the ML models are therefore robust and can serve as a prioritization tool to drive and guide phenotypic screening and medicinal chemistry programs. For Table of Contents Graphic Only:
Open AccessMachine learning approaches identify chemical features for stage-specific antimalarial compounds
Efficacy data from diverse chemical libraries, screened against the various stages of the malaria parasite Plasmodium falciparum , including asexual blood stage (ABS) parasites and transmissible gametocytes, serves as a valuable reservoir of information on the chemical space of compounds that are either active (or not) against the parasite. We postulated that this data can be mined to define chemical features associated with sole ABS activity and/or those that provide additional life cycle activity profiles like gametocytocidal activity. Additionally, this information could provide chemical features associated with inactive compounds, which could eliminate any future unnecessary screening of similar chemical analogues. Therefore, we aimed to use machine learning to identify the chemical space associated with stage-specific antimalarial activity. We collected data from various chemical libraries that were screened against the asexual (126 374 compounds) and sexual (gametocyte) stages of the parasite (93 941 compounds), calculated the compounds’ molecular fingerprints and trained machine learning models to recognize stage-specific active and inactiv compounds. We were able to build several models that predicts compound activity against ABS and dual-activity against ABS and gametocytes, with Support Vector Machines (SVM) showing superior abilities with high recall (90% and 66%) and low false positive predictions (15% and 1%). This allowed identification of chemical features enriched in active and inactive populations, an important outcome that could be mined for essential chemical features to streamline hit-to-lead optimization strategies of antimalarial candidates. The predictive capabilities of the models held true in diverse chemical spaces, indicating that the ML models are therefore robust and can serve as a prioritization tool to drive and guide phenotypic screening and medicinal chemistry programs. For Table of Contents Graphic Only:
- Open Access
First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool to train small-molecule activity prediction models. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets, ranging from whole-cell growth inhibition assays to drug metabolism properties. The tool has been implemented end-to-end at the Holistic Drug Discovery and Development (H3D) Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. We have exploited in-house data collected from over a decade of drug discovery research in malaria and tuberculosis and built models to predict the outcomes of 15 key checkpoint assays. We subsequently deployed these models as a virtual screening cascade at an organisational scale to increase the hit rate of current experimental assays. We show how computational profiling of compounds, prior to synthesis and experimental testing, can increase the rate of progression by up to 40%. Moreover, we demonstrate that the approach can be applied to prioritise small molecules within a chemical series and to assess the likelihood of success of novel chemotypes, promoting efficient usage of limited experimental resources. This project is part of a first-of-its-kind collaboration between the H3D Centre, a research centre operating in a low-resource setting, and the Ersilia Open Source Initiative, a young tech non-profit devoted to building data science capacity in the Global South.
Open AccessFirst fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool to train small-molecule activity prediction models. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets, ranging from whole-cell growth inhibition assays to drug metabolism properties. The tool has been implemented end-to-end at the Holistic Drug Discovery and Development (H3D) Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. We have exploited in-house data collected from over a decade of drug discovery research in malaria and tuberculosis and built models to predict the outcomes of 15 key checkpoint assays. We subsequently deployed these models as a virtual screening cascade at an organisational scale to increase the hit rate of current experimental assays. We show how computational profiling of compounds, prior to synthesis and experimental testing, can increase the rate of progression by up to 40%. Moreover, we demonstrate that the approach can be applied to prioritise small molecules within a chemical series and to assess the likelihood of success of novel chemotypes, promoting efficient usage of limited experimental resources. This project is part of a first-of-its-kind collaboration between the H3D Centre, a research centre operating in a low-resource setting, and the Ersilia Open Source Initiative, a young tech non-profit devoted to building data science capacity in the Global South.
- 30 June 2022
- Published by Cassyni
Ersilia, a hub of open-source AI/ML models for drug discovery and global health
The Ersilia Open Source Initiative (EOSI) is a non-profit organisation whose mission is to strengthen the research capacity in LMIC. EOSI is focussed on disseminating and deploying artificial intelligence and machine learning (AI/ML) tools for drug discovery as a solution to minimise the cost and number of laboratory experiments. The main asset of EOSI is the Ersilia Model Hub, a free, online, open-source platform where scientists can browse through a catalogue of AI/ML models, select the ones that are relevant to their research and run online predictions without the need to write a single line of code. We gather, in a single resource, two classes of models. On the one hand, we collect models developed by third parties and available in scientific publications. On the other hand, we develop models in- house and/or in collaboration with research groups that operate in underserved settings. In this introductory talk, we will present our computational approach and infrastructure, with the goal of identifying potential collaborations and synergies between EOSI and Kenyatta University.
- 30 June 2022
- Published by Cassyni
Ersilia, a hub of open-source AI/ML models for drug discovery and global health
The Ersilia Open Source Initiative (EOSI) is a non-profit organisation whose mission is to strengthen the research capacity in LMIC. EOSI is focussed on disseminating and deploying artificial intelligence and machine learning (AI/ML) tools for drug discovery as a solution to minimise the cost and number of laboratory experiments. The main asset of EOSI is the Ersilia Model Hub, a free, online, open-source platform where scientists can browse through a catalogue of AI/ML models, select the ones that are relevant to their research and run online predictions without the need to write a single line of code. We gather, in a single resource, two classes of models. On the one hand, we collect models developed by third parties and available in scientific publications. On the other hand, we develop models in- house and/or in collaboration with research groups that operate in underserved settings. In this introductory talk, we will present our computational approach and infrastructure, with the goal of identifying potential collaborations and synergies between EOSI and Kenyatta University.